Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
237,580
Any status, any sponsor type
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting22,408
- Not yet recruiting9,484
- Completed134,382
237,580 trials
Showing 1 to 25, recently updated first.
- A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China ExtensionPivotal-lookingTerminated
GlaxoSmithKlineGSK (GSK)
NCT07650084 · 75 participants · Start Nov 21, 2025 · Primary completion Jul 17, 2026
Drug: BLU-5937; Placebo · For: Refractory Chronic Cough
Sites: Leshan, China; Beijing, China; Changsha, China · 38 sites in all
Haihua YuanAcademic, hospital or other
NCT07631871 · 10 participants (planned) · Start May 12, 2026 · Primary completion Dec 31, 2029
Drug: Zanidatamab · For: Neoplasms; Solid Tumors; HER2 Positive Solid Tumor and 7 more
Sites: Shanghai, China
- Evaluating the Efficacy and Safety of SAL0167 Tablets at Different Doses in Participants With Hyperlipidemia.Pivotal-lookingNot yet recruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07951411 · 240 participants (planned) · Start Dec 31, 2026 · Primary completion Jul 30, 2027
Drug: SAL0167 Dose 1; SAL0167 Dose 2 and 2 more · For: Hyperlipidemia
Sites: Beijing, China
National Cancer Institute (NCI)NIH
NCT06149481 · 60 participants (planned) · Start Mar 26, 2024 · Primary completion Oct 31, 2027
Drug: Retifanlimab; Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform and 2 more · For: Metastatic Colorectal Cancer
Sites: Bethesda, Maryland
- Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASDPivotal-lookingRecruiting
Shanghai Auzone Biological Technology Co., Ltd.Industry
NCT06757504 · 150 participants (planned) · Start Jan 13, 2025 · Primary completion Jun 30, 2027
Drug: TTYP01 Tablets (12mg or 18mg); Placebo (Simulant TTYP01 Tablets) · For: Autism Spectrum Disorder (ASD)
Sites: Beijing, China; Changsha, China; Chengdu, China · 5 sites in all
- A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate CancerActive, not recruiting
Syncromune, Inc.Industry
NCT06533644 · 91 participants (planned) · Start May 29, 2025 · Primary completion Apr 14, 2028
Drug: SV-102 · For: Metastatic Castration-resistant Prostate Cancer
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 23 sites in all
Abhay Singh, MD MPHAcademic, hospital or other
NCT06630221 · 25 participants (planned) · Start Jun 17, 2025 · Primary completion Jan 1, 2028
Drug: Eltrombopag (EPAG) · For: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia
Sites: Cleveland, Ohio
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerActive, not recruiting
Olema Oncology, Inc.Industry
NCT05508906 · 190 participants (planned) · Start Aug 31, 2022 · Primary completion Dec 31, 2027
Drug: Palazestrant; Ribociclib and 3 more · For: Metastatic Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer and 2 more
Sites: Gilbert, Arizona; San Francisco, California; Aurora, Colorado · 16 sites in all
- Sleep Quality - Comparing the Effect of Ondansetron or Dexamethasone Given as Routine Prophylaxis Intraoperatively to Prevent Post Operative Nausea and Vomiting (SCORPION)Pivotal-lookingRecruiting
Telethon Kids InstituteAcademic, hospital or other
NCT07777276 · 500 participants (planned) · Start Aug 3, 2026 · Primary completion Aug 17, 2029
Drug: Dexamethasone (IV); Ondansetron iv · For: Postoperative Sleep Quality; Postoperative Behaviour; Postoperative Recovery in Children and 3 more
Sites: Perth, Australia; São Paulo, Brazil · 3 sites in all
Stony Brook UniversityAcademic, hospital or other
NCT04814355 · 50 participants (planned) · Start Aug 1, 2018 · Primary completion Aug 31, 2028
Drug: Celecoxib 400 mg · For: Major Depressive Disorder; Neuroinflammation
Sites: Stony Brook, New York
- Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
United TherapeuticsIndustry
NCT04708782 · 598 participants · Start Apr 21, 2021 · Primary completion Feb 2, 2026
Drug: Placebo; Inhaled Treprostinil · For: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 96 sites in all
- Compassionate Use of Metreleptin in Previously Treated People With Generalized LipodystrophyPivotal-lookingActive, not recruiting
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT02262832 · 24 participants · Start Oct 9, 2014 · Primary completion Jul 31, 2027
Drug: Metreleptin · For: Lipodystrophy; Diabetes; Hyperlipidemia
Sites: Bethesda, Maryland
Hangzhou Converd Co., Ltd.Industry
NCT07185243 · 24 participants (planned) · Start Jun 23, 2025 · Primary completion Jun 2027
Drug: recombinant human IL-21-expressing oncolytic vaccinia virus injection · For: Advanced Solid Tumors
Sites: Xiamen, China
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT07391774 · 1,978 participants (planned) · Start Aug 10, 2026 · Primary completion Jul 31, 2029
Drug: Anastrozole; Chemotherapy and 3 more · For: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8 and 2 more
Sites: Jonesboro, Arkansas; Auburn, California; Berkeley, California · 264 sites in all
- Human Experimental Models of Pain (HEMP)Not yet recruiting
National Center for Complementary and Integrative Health (NCCIH)NIH
NCT07549490 · 25 participants (planned) · Start Nov 25, 2026 · Primary completion Dec 31, 2029
Drug: Placebo; Naproxen and 1 more · For: Acute Pain
Sites: Bethesda, Maryland
Qilu Hospital of Shandong UniversityAcademic, hospital or other
NCT06932068 · 77 participants (planned) · Start Mar 26, 2025 · Primary completion Oct 31, 2027
Drug: Iparomlimab and Tuvonralimab (QL1706); Oxaliplatin and 1 more · For: HER2 Negative; Low PD-L1 Expressing; Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Sites: Zhengzhou, China; Binzhou, China; Dezhou, China · 29 sites in all
- Long-Term Open-Label Extension Study of Oral LevosimendanPivotal-lookingEnrolling by invitation
Tenax Therapeutics, Inc.Industry
NCT07436689 · 800 participants (planned) · Start Mar 13, 2026 · Primary completion Mar 2029
Drug: TNX-103 · For: Pulmonary Hypertension Associated With HFpEF
Sites: Chicago, Illinois; Indianapolis, Indiana; Boston, Massachusetts · 14 sites in all
- GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant AscitesPivotal-lookingRecruiting
Kyushu UniversityAcademic, hospital or other
NCT05438459 · 176 participants (planned) · Start Jun 8, 2022 · Primary completion Mar 31, 2032
Drug: GAIA-102; GAIA-102 and 6 more · For: Gastric Cancer; Pancreatic Cancer
Sites: Fukuoka, Japan
- A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) SyndromePivotal-lookingNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07569081 · 136 participants (planned) · Start Nov 2, 2026 · Primary completion Dec 19, 2028
Drug: Momelotinib; Glucocorticoids and 1 more · For: VEXAS Syndrome
Sites: Houston, Texas; Salzburg, Austria; Tokyo, Japan
Triastek, lnc.Industry
NCT07951138 · 18 participants (planned) · Start Nov 16, 2026 · Primary completion Dec 19, 2026
Drug: Itraconazole Tablet(T26); Sporanox® · For: Fungal Infections
Sites: Chongqing, China
Virginia Commonwealth UniversityAcademic, hospital or other
NCT06185205 · 170 participants (planned) · Start Dec 12, 2023 · Primary completion Jan 31, 2031
Drug: Accelerated partial breast irradiation · For: Breast Cancer
Sites: Richmond, Virginia
Fortvita Biologics (USA)Inc.Industry
NCT07842393 · 32 participants (planned) · Start Oct 20, 2026 · Primary completion Mar 2, 2027
Drug: Investigational Drug: IBI3042; Matching Placebo · For: Healthy Volunteers (HV)
Sites: Lenexa, Kansas
AstraZenecaAstraZeneca (AZN)
NCT06103864 · 625 participants (planned) · Start Nov 23, 2023 · Primary completion Jul 28, 2027
Drug: Dato-DXd; Durvalumab and 5 more · For: Breast Cancer
Sites: Daphne, Alabama; Springdale, Arkansas; Duarte, California · 318 sites in all
- Clinical Trial to Evaluate the Protective Effect of Larazotide Acetate in Individuals With Well-Controlled Celiac DiseasePivotal-lookingNot yet recruiting
Interlude Biopharma Co.Industry
NCT07944625 · 414 participants (planned) · Start Feb 2027 · Primary completion Aug 2028
Drug: Larazotide Acetate; Placebo · For: Celiac Disease; Celiac Disease in Adolescents
- ctDNA-Guided Neoadjuvant Therapy in HER2+ Breast CancerNot yet recruiting
Jin Sun BitarAcademic, hospital or other
NCT07950007 · 60 participants (planned) · Start Feb 1, 2027 · Primary completion Aug 1, 2029
Drug: T-DXd · For: HER2 + Breast Cancer
Sites: Beverly Hills, California
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.